YDESHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 8 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores YD Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (72): The share price has been relatively steady.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on YDES, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YDES appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, YD Bio Ltd. returned −66.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 2% of US stocks
Cheaper than 63% of US stocks
Cheaper than 95% of US stocks
Higher than 97% of US stocks
Higher than 8% of US stocks
Higher than 86% of US stocks
Higher than 99% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
YD Bio Ltd. has a market value of $416.5M and an enterprise value of $433.0M.
Trailing P/E: −48.3×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
YD Bio Ltd. employs 13 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own YD Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
YD Bio and EG BioMed announced the launch of an AI-based assessment of risk factors for 10 cancers.
Why it matters — The announcement concerns a cancer-risk assessment initiative involving YD Bio and its DNA methylation-based cancer detection focus.
YD Bio Limited, a Nasdaq-listed biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced its unaudited financial results for the six months ended June 30, 2026. The announcement was made via GlobeNewsWire on August 31, 2026.
Why it matters — A YDES watcher would look to this interim financial disclosure for an update on the company's performance and fiscal standing during the first half of 2026.
YD Bio announced the publication of a peer-reviewed review article in the journal Nutrients, titled "Beyond Bone Health: Exploring the 'Heart–Brain–Bone' Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2)." The article was co-authored by members of the Company's scientific team together with physicians from the Taiwan Chronic Disease Healthcare Association, the Future Health Institute, and Taipei Medical University Hospital, among others.
Why it matters — This peer-reviewed publication lends scientific visibility and external credibility to YD Bio's research collaborations, which YDES watchers would view as a notable achievement for the company's profile.
YD Bio launched a six-month pilot collaboration with Numia Health to evaluate bringing its blood-based OkaiDx cancer tests to patients in British Columbia, Canada through a cross-border clinical workflow involving mobile blood collection and testing at a US laboratory.
Why it matters — The pilot represents a step toward expanding YD Bio's molecular diagnostics into the Canadian market and testing the scalability of its cross-border testing model.
As at 8 Oct 2026, YD Bio Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (72 of 100).
No analyst covering YD Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YDES are extrapolating price history, which says nothing about the business.
YD Bio Ltd. returned -66.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment". YD Bio and EG BioMed announced the launch of an AI-based assessment of risk factors for 10 cancers.
YD Bio Limited is a biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Its current portfolio includes DNA methylation-based cancer detection programs, ophthalmologic products, stem cell- and exosome-based therapeutics, and clinical trial drug supply services. The company also works in blood-based oncology testing, early cancer detection, treatment monitoring, and recurrence tracking, while serving pharmaceutical and biotechnology partners with compliant distribution and clinical trial support. Based in Taipei, Taiwan, YD Bio Limited operates as an integrated healthcare platform spanning diagnostics, regenerative medicine, eye care, and related commercial healthcare markets.
CEO Dr. Ethan Shen Ph.D. · 13 employees · Taiwan · https://www.ydesgroup.com
